{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:37:30Z","timestamp":1793450250348,"version":"4.5.0"},"reference-count":285,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["CIRCLE - 101041424"],"award-info":[{"award-number":["CIRCLE - 101041424"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["12\/RC\/2275_P2"],"award-info":[{"award-number":["12\/RC\/2275_P2"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","award":["GOIPG\/2021\/1649"],"award-info":[{"award-number":["GOIPG\/2021\/1649"]}],"id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["EIA-2019-006"],"award-info":[{"award-number":["EIA-2019-006"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jconrel.2023.12.012","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T20:47:01Z","timestamp":1706215621000},"page":"812-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol"],"prefix":"10.1016","volume":"366","author":[{"given":"Michael T.","family":"Neary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne M.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr S.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"MacLoughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abina M.","family":"Crean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie B.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0005","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis."},{"issue":"7","key":"10.1016\/j.jconrel.2023.12.012_bb0010","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.amjcard.2018.06.023","article-title":"Effectiveness and safety of inclisiran, a novel long-acting RNA therapeutic inhibitor of proprotein convertase subtilisin\/kexin 9","volume":"122","author":"Chandra Ghosh","year":"2018","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4068\/cmj.2020.56.2.87","article-title":"RNA therapy: current status and future potential","volume":"56","author":"Kim","year":"2020","journal-title":"Chonnam Med. J."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb4020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt.1802","article-title":"Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria","volume":"108","author":"Agarwal","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"10.1016\/j.jconrel.2023.12.012_bb0020","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0025","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0035","series-title":"MicroRNA-145 Targeted Therapy Reduces Atherosclerosis","author":"Lovren","year":"2012"},{"issue":"14","key":"10.1016\/j.jconrel.2023.12.012_bb0040","first-page":"S226","article-title":"Short hairpin RNA interference therapy for ischemic heart disease","volume":"118","author":"Huang","year":"2008","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0045","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0050","first-page":"141","article-title":"Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown","volume":"629","author":"Moore","year":"2010","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb0055","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of Patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.pharmthera.2005.03.004","article-title":"RNA interference: from gene silencing to gene-specific therapeutics","volume":"107","author":"Leung","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nbt936","article-title":"Rational siRNA Design for RNA Interference","volume":"22","author":"Reynolds","year":"2004","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2005.06.023","article-title":"RNAi: The nuts and bolts of the RISC machine","volume":"122","author":"Filipowicz","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature07755","article-title":"A three-dimensional view of the molecular machinery of RNA interference","volume":"457","author":"Jinek","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113834","article-title":"Nucleic acid delivery for therapeutic applications","author":"Gupta","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0085","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jacc.2021.01.008","article-title":"Inclisiran: a game changer in a changing game?","volume":"77","author":"Nambi","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0090","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2022.100063","article-title":"siRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy","volume":"7","author":"Paul","year":"2022","journal-title":"OpenNano"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0105","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mt.2009.91","article-title":"The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice","volume":"17","author":"Gao","year":"2009","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0110","first-page":"1","article-title":"Delivery systems for siRNA drug development in cancer therapy","volume":"10","author":"Xu","year":"2015","journal-title":"Asian J. Pharmaceut. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2023.12.012_bb0115","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"21","key":"10.1016\/j.jconrel.2023.12.012_bb0120","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","article-title":"The medicinal chemistry of therapeutic oligonucleotides","volume":"59","author":"Brad Wan","year":"2016","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0125","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cbpa.2004.10.007","article-title":"RNA interference and chemically modified small interfering RNAs","volume":"8","author":"Manoharan","year":"2004","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0130","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.12.012_bib1407","doi-asserted-by":"crossref","unstructured":"L.E. Mays et al., Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. J. Clin. Invest. 123(3) (2013) 1216-28, https:\/\/doi.org\/10.1172\/JCI65351. Epub 2013 Feb 8. PMID: 23391720 PMCID: PMC3582134.","DOI":"10.1172\/JCI65351"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0145","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat. Commun."},{"issue":"48","key":"10.1016\/j.jconrel.2023.12.012_bb0155","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1073\/pnas.1908052116","article-title":"mRNA structure regulates protein expression through changes in functional half-life","volume":"116","author":"Mauger","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0165","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case","volume":"112","author":"Oude Blenke","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0170","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/acs.bioconjchem.6b00090","article-title":"Effects of chemically modified messenger RNA on protein expression","volume":"27","author":"Li","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00861-4","article-title":"Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0180","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-020-00014-z","article-title":"Developing inhaled protein therapeutics for lung diseases","volume":"1","author":"Matthews","year":"2020","journal-title":"Mol. Biomed."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0185","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0431-x","article-title":"Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma","volume":"6","author":"Lai","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb0190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1369\/0022155411410885","article-title":"Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery","volume":"59","author":"Shi","year":"2011","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0195","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2147\/IJN.S291421","article-title":"Immunotherapy of tumor RNA-loaded lipid nanoparticles against hepatocellular carcinoma","volume":"16","author":"Zhang","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0200","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle\u2013liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"issue":"25","key":"10.1016\/j.jconrel.2023.12.012_bb0205","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1016\/j.biomaterials.2012.05.002","article-title":"Lipid nanoparticles for hepatic delivery of small interfering RNA","volume":"33","author":"Yu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0210","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0215","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jconrel.2022.03.046","article-title":"The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs","volume":"345","author":"LoPresti","year":"2022","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0220","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/acs.nanolett.2c04479","article-title":"The transcriptional response to lung-targeting lipid nanoparticles in vivo","volume":"23","author":"Radmand","year":"2023","journal-title":"Nano Lett."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0225","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41565-021-01030-y","article-title":"Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles","volume":"17","author":"Hatit","year":"2022","journal-title":"Nat. Nanotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0230","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120994","article-title":"Progress in nasal drug delivery systems","volume":"607","author":"Laffleur","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0240","series-title":"Engineered mutant \u03b1-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models","author":"Mukherjee","year":"2020"},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1634","article-title":"T-cell targeted pulmonary siRNA delivery for the treatment of asthma","volume":"12","author":"Keil","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0250","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1165\/rcmb.2008-0363OC","article-title":"Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with mycobacterium tuberculosis","volume":"41","author":"Rosas-Taraco","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"7","key":"10.1016\/j.jconrel.2023.12.012_bb0255","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/14760584.2021.1903878","article-title":"Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19","volume":"21","author":"Heida","year":"2022","journal-title":"Expert Rev. Vaccine"},{"issue":"49","key":"10.1016\/j.jconrel.2023.12.012_bb0260","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1016\/j.vaccine.2014.08.089","article-title":"The mucosal immune system for vaccine development","volume":"32","author":"Lamichhane","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0265","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.copbio.2021.10.017","article-title":"Inhalable mRNA vaccines for respiratory diseases: a roadmap","volume":"74","author":"Roh","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0270","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1021\/acsnano.2c05647","article-title":"Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation","volume":"16","author":"Kim","year":"2022","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0275","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1089\/jamp.2017.1364","article-title":"Hybrid lipid\/polymer nanoparticles for pulmonary delivery of siRNA: development and fate upon in vitro deposition on the human epithelial airway barrier","volume":"31","author":"D\u2019Angelo","year":"2018","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0280","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","article-title":"Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents","volume":"39","author":"Blanchard","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0285","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00161-2018","article-title":"Nebulised lipid-polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells","volume":"5","author":"Vencken","year":"2019","journal-title":"ERJ Open Res"},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0290","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb0295","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/tde-2017-0037","article-title":"Drug delivery to the lungs: Challenges and opportunities","volume":"8","author":"Newman","year":"2017","journal-title":"Ther. Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0300","article-title":"Magnetic core-shell nanoparticles for drug delivery by nebulization","volume":"11","author":"Kumar Verma","year":"2013","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00113-L","article-title":"Mechanisms of macromolecule absorption by the lungs","volume":"19","author":"Patton","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0310","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2003.10.001","article-title":"Absorption enhancers in pulmonary protein delivery","volume":"94","author":"Hussain","year":"2004","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0315","first-page":"198","article-title":"The Lung as a Route for Systemic Delivery of Therapeutic Proteins and Peptides","volume":"2","author":"Agu","year":"2001","journal-title":"Respir Res"},{"issue":"7","key":"10.1016\/j.jconrel.2023.12.012_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/nano10071248","article-title":"In vitro and in vivo assessment of PEGylated PEI for anti-IL-8\/CxCL-1 siRNA delivery to the lungs","volume":"10","author":"Hibbitts","year":"2020","journal-title":"Nanomaterials"},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13081281","article-title":"In vitro investigations on optimizing and nebulization of ivt-mrna formulations for potential pulmonary-based alpha-1-antitrypsin deficiency treatment","volume":"13","author":"Guan","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109706","article-title":"Protein and peptide delivery to lungs by using advanced targeted drug delivery","volume":"351","author":"Chellappan","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0335","series-title":"Mechanical Ventilation amid the COVID-19 Pandemic a Guide for Physicians and Engineers","author":"Hakimi","year":"2022"},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0340","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4103\/0019-5049.165849","article-title":"Anatomy and physiology of respiratory system relevant to anaesthesia","volume":"59","author":"Patwa","year":"2015","journal-title":"Indian J. Anaesthesia"},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0345","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201212-2260OE","article-title":"It takes more than cells to make a good lung","volume":"187","author":"Weibel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0350","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.medengphy.2017.03.004","article-title":"Penetration of inhaled aerosols in the bronchial tree","volume":"44","author":"Miguel","year":"2017","journal-title":"Med. Eng. Phys."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0355","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.prrv.2009.12.006","article-title":"Normal development of the lung and premature birth","volume":"11","author":"Smith","year":"2010","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0360","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.colsurfa.2017.12.042","article-title":"Effects of the conformation of PLGA molecules in the organic solvent on the aerodynamic diameter of spray dried microparticles","volume":"539","author":"Nii","year":"2018","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0375","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/aps.2017.34","article-title":"Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities","volume":"38","author":"Mangal","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"12","key":"10.1016\/j.jconrel.2023.12.012_bb0365","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol."},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb0370","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.rmed.2014.05.009","article-title":"The clinical relevance of dry powder inhaler performance for drug delivery","volume":"108","author":"Demoly","year":"2014","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bib1406","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/jamp.2011.0916","article-title":"Aerosol deposition in health and diseas","volume":"25","author":"Chantal","year":"2012","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"issue":"11","key":"10.1016\/j.jconrel.2023.12.012_bb0385","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/jac\/dkv192","article-title":"Pulmonary drug delivery: A review on nanocarriers for antibacterial chemotherapy","volume":"70","author":"Moreno-Sastre","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0390","article-title":"Inhaled nano -and microparticles for drug delivery","volume":"2015","author":"El-Sherbiny","year":"2015","journal-title":"Global Cardiol. Sci. Pract."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0395","first-page":"66","article-title":"Particle size determination of nasal drug delivery system: a review","volume":"17","author":"Sangolkar","year":"2012","journal-title":"Int. J Pharm Sci Rev Res"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0400","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0378-5173(02)00526-4","article-title":"Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique","volume":"249","author":"De Boer","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0405","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/jamp.2020.29028.whf","article-title":"Particle size distributions","volume":"33","author":"Finlay","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"7","key":"10.1016\/j.jconrel.2023.12.012_bb0410","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0021-8502(97)00017-7","article-title":"Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols","volume":"28","author":"Finlay","year":"1997","journal-title":"J. Arrosol Sci."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0415","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14356\/kona.2004010","article-title":"Particle size analysis of aerosols from medicinal inhalers","volume":"22","author":"Mitchell","year":"2004","journal-title":"Kona Powder Part. J."},{"issue":"19","key":"10.1016\/j.jconrel.2023.12.012_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/app11199283","article-title":"Modelling spray pressure effects on droplet size distribution from agricultural nozzles","volume":"11","author":"Cerruto","year":"2021","journal-title":"Appl. Sci."},{"issue":"32","key":"10.1016\/j.jconrel.2023.12.012_bb0425","first-page":"1","article-title":"Particulate matter measurement by using the particle sizers APS and SMPS","volume":"8","author":"Holub\u010d\u00edk","year":"2021","journal-title":"EAI Endorsed Transact. Energy Web"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0430","doi-asserted-by":"crossref","DOI":"10.1063\/5.0018667","article-title":"Drop size measurement techniques for sprays: comparison of image analysis, phase Doppler particle analysis, and laser diffraction","volume":"11","author":"Sijs","year":"2021","journal-title":"AIP Adv."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb0435","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/clinids\/19.5.916","article-title":"Cellular Transport of Drugs","volume":"19","author":"Steinberg","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0440","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2018.06.017","article-title":"Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA","volume":"284","author":"Sato","year":"2018","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0445","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2012.05.018","article-title":"Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment","volume":"434","author":"Gomes-Da-Silva","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb0450","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"11","key":"10.1016\/j.jconrel.2023.12.012_bb0455","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109561","article-title":"Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)","volume":"125","author":"Song","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0465","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1021\/acsbiomaterials.7b00971","article-title":"Tumor-penetrating peptide-functionalized redox-responsive Hyperbranched poly(amido amine) delivering siRNA for lung Cancer therapy","volume":"4","author":"Guo","year":"2018","journal-title":"ACS Biomater Sci. Eng."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0470","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2014.03.034","article-title":"Endosome maturation, transport and functions","volume":"31","author":"Scott","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0475","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-015-0041-1","article-title":"The Endosomal-Lysosomal System: From Acidification and Cargo Sorting to Neurodegeneration","volume":"4","author":"Hu","year":"2015","journal-title":"Transl Neurodegener"},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0480","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1021\/mp800176t","article-title":"Target specific intracellular delivery of siRNA\/PEI-HA complex by receptor mediated endocytosis","volume":"6","author":"Jiang","year":"2008","journal-title":"Mol. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0485","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijpharm.2008.09.039","article-title":"Polymeric nanoparticles for siRNA delivery and gene silencing","volume":"367","author":"Patil","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0490","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1021\/bc800065f","article-title":"Simple Modifications of Branched PEI Lead to Highly Efficient siRNA Carriers with Low Toxicity","volume":"19","author":"Zintchenko","year":"2008","journal-title":"Bioconjugate Chem."},{"issue":"45","key":"10.1016\/j.jconrel.2023.12.012_bb0495","doi-asserted-by":"crossref","first-page":"44826","DOI":"10.1074\/jbc.M308643200","article-title":"Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA Polyplexes","volume":"278","author":"Sonawane","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2023.12.012_bb0500","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/nbt1161","article-title":"Activation of the mammalian immune system by siRNAs","volume":"23","author":"Marques","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0505","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.molmed.2006.02.004","article-title":"Innate sensing of self and non-self RNAs by toll-like receptors","volume":"12","author":"Sioud","year":"2006","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0510","article-title":"The Pivotal Role of Chemical Modifications in mRNA Therapeutics","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0515","series-title":"Regulation of Mucociliary Clearance in Health and Disease","author":"Houtmeyers","year":"1999"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0520","series-title":"The Effect of Cilia and the Mucociliary Clearance on Successful Drug Delivery","author":"Gizurarson","year":"2015"},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2023.12.012_bb0525","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cocis.2005.11.001","article-title":"Mucin structure, aggregation, physiological functions and biomedical applications","volume":"11","author":"Bansil","year":"2006","journal-title":"Curr. Opin. Colloid Interface Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0530","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1007\/s13346-021-00954-1","article-title":"Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections","volume":"11","author":"Huang","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0535","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","article-title":"Nasal Mucociliary Clearance as a Factor in Nasal Drug Delivery","volume":"29","author":"Marttin","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0540","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0954-6111(94)90020-5","article-title":"The Assessment of Nasal Mucociliary Clearance and the Effect of Drugs","volume":"88","author":"Rusznak","year":"1994","journal-title":"Respir Med."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","volume":"11","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.jconrel.2023.12.012_bb0550","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/mt.2016.182","article-title":"The mucus barrier to inhaled gene therapy","volume":"24","author":"Duncan","year":"2016","journal-title":"Mol. Ther."},{"issue":"23","key":"10.1016\/j.jconrel.2023.12.012_bb0555","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra0910061","article-title":"Airway Mucus Function and Dysfunction","volume":"363","author":"Fahy","year":"2010","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0560","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1165\/rcmb.2006-0082SF","article-title":"Effective mucus clearance is essential for respiratory health","volume":"35","author":"Randell","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0565","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MCP.0b013e32831da8d3","article-title":"Mucus hypersecretion in asthma: causes and effects","volume":"15","author":"Evans","year":"2009","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0570","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2012.06.005","article-title":"An inhalable \u03b22-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung","volume":"162","author":"Luo","year":"2012","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0575","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijpharm.2013.07.024","article-title":"Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery","volume":"455","author":"Sharma","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0580","article-title":"Chitosan nanoparticle-based system: a new insight into the promising controlled release system for lung cancer treatment","volume":"27","author":"Kuen","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0585","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9040053","article-title":"An overview of chitosan nanoparticles and its application in non-parenteral drug delivery","volume":"9","author":"Mohammed","year":"2017","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0590","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0595","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejpb.2014.12.021","article-title":"In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration","volume":"97","author":"Inchaurraga","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"10","key":"10.1016\/j.jconrel.2023.12.012_bb0600","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1021\/mp500332m","article-title":"On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein","volume":"11","author":"Mun","year":"2014","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0605","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2004.04.026","article-title":"Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density","volume":"98","author":"Vila","year":"2004","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0610","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijpharm.2016.02.031","article-title":"Enhanced pulmonary delivery of fluticasone propionate in rodents by mucus-penetrating nanoparticles","volume":"502","author":"Popov","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0615","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"PEGylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"13","key":"10.1016\/j.jconrel.2023.12.012_bb0620","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.biomaterials.2013.01.064","article-title":"Nanoparticle diffusion in respiratory mucus from humans without lung disease","volume":"34","author":"Schuster","year":"2013","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.jconrel.2023.12.012_bb0625","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.biomaterials.2008.12.076","article-title":"The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles","volume":"30","author":"Suk","year":"2009","journal-title":"Biomaterials"},{"issue":"28","key":"10.1016\/j.jconrel.2023.12.012_bb0630","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1073\/pnas.1502281112","article-title":"Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy","volume":"112","author":"Mastorakos","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"26","key":"10.1016\/j.jconrel.2023.12.012_bb0635","doi-asserted-by":"crossref","first-page":"11414","DOI":"10.1039\/D1NR02179F","article-title":"Multi-component bioresponsive nanoparticles for synchronous delivery of docetaxel and TUBB3 siRNA to lung cancer cells","volume":"13","author":"Conte","year":"2021","journal-title":"Nanoscale"},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb0640","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0885328219863291","article-title":"Mucopenetrating lipoplexes modified with PEG and hyaluronic acid for CD44-targeted local siRNA delivery to the lungs","volume":"34","author":"Almeida","year":"2019","journal-title":"J. Biomater. Appl."},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0645","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.95.4.1579","article-title":"Dynamics of surfactant release in alveolar type II cells","volume":"95","author":"Haller","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0650","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/(SICI)1521-2254(199909\/10)1:5<331::AID-JGM60>3.0.CO;2-8","article-title":"Interaction of Liposomal and Polycationic Transfection Complexes with Pulmonary Surfactant","volume":"1","author":"Ernst","year":"1999","journal-title":"J. Gene Med."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0655","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijpharm.2016.01.038","article-title":"Biokinetic studies of non-complexed siRNA versus nano-sized PEI F25-LMW\/siRNA polyplexes following intratracheal instillation into mice","volume":"500","author":"Lipka","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0660","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.addr.2014.05.018","article-title":"SiRNA Delivery to the lung: What\u2019s new?","volume":"75","author":"Merkel","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0665","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2015.08.030","article-title":"Hybrid pulmonary surfactant-coated nanogels mediate efficient in vivo delivery of siRNA to murine alveolar macrophages","volume":"217","author":"De Backer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0670","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejpb.2020.09.011","article-title":"Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy","volume":"157","author":"Merckx","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0675","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jconrel.2007.01.013","article-title":"Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages","volume":"119","author":"Hirota","year":"2007","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0680","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijpharm.2018.09.031","article-title":"Inhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles","volume":"551","author":"Hu","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2011.02.006","article-title":"Pulmonary delivery of therapeutic siRNA","volume":"64","author":"Lam","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0690","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2008.06.010","article-title":"Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy","volume":"132","author":"Nguyen","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0695","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1152\/physrev.00002.2012","article-title":"Role of phospholipids in endocytosis, phagocytosis, and mac-ropinocytosis","volume":"93","author":"Bohdanowicz","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0700","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.607945","article-title":"Modulation of immune responses by particle size and shape","volume":"11","author":"Baranov","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2022.102134","article-title":"Inhaled delivery of a lipid nanoparticle encapsulated messenger RNA encoding a ciliary protein for the treatment of primary ciliary dyskinesia","volume":"75","author":"Woo","year":"2022","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb0710","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1113\/jphysiol.2011.222091","article-title":"VAMP8 is a vesicle SNARE that regulates mucin secretion in airway goblet cells","volume":"590","author":"Jones","year":"2012","journal-title":"J. Physiol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0715","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1039\/C9NR06382J","article-title":"Targeted delivery of Chil3\/Chil4 siRNA to alveolar macrophages using ternary complexes composed of HMG and oligoarginine micelles","volume":"12","author":"Choi","year":"2020","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0720","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10280","article-title":"Macrophage-targeted delivery of siRNA to silence Mecp2 gene expression attenuates pulmonary fibrosis","volume":"7","author":"Mou","year":"2022","journal-title":"Bioeng Transl Med"},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0725","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jamp.2011-0966","article-title":"Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice","volume":"26","author":"Mainelis","year":"2013","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0730","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jaci.2010.01.003","article-title":"Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up","volume":"125","author":"Contoli","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0735","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/07853890600585795","article-title":"Treatment of airway mucus hypersecretion","volume":"38","author":"Rogers","year":"2006","journal-title":"Ann. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2023.12.012_bb0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12111042","article-title":"Aerosolizable lipid nanoparticles for pulmonary delivery of mRNA through design of experiments","volume":"12","author":"Zhang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0745","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9086-3_1","article-title":"The applicability of mouse models to the study of human disease","volume":"vol. 1940","author":"Rydell-T\u00f6rm\u00e4nen","year":"2019"},{"key":"10.1016\/j.jconrel.2023.12.012_bib1408","doi-asserted-by":"crossref","unstructured":"Arun V. Kolanjiyil, Clement Kleinstreuer, Nicole C. Kleinstreuer, Wellington Pham, Ruxana T. Sadikot. 2019. Mice-to-men comparison of inhaled drug-aerosol deposition and clearance. Respir. Physiol. Neurobiol. 260: 82-94. https:\/\/doi.org\/10.1016\/j.resp.2018.11.003. Epub 2018 Nov 13. PMID: 30445230.","DOI":"10.1016\/j.resp.2018.11.003"},{"key":"10.1016\/j.jconrel.2023.12.012_bib1409","doi-asserted-by":"crossref","unstructured":"A. Guillon, T. S\u00e9cher, L.A. Dailey, L. Vecellio, M. de Monte, M. Si-Tahar, P. Diot, C.P. Page, N. Heuz\u00e9-Vourc'h. 2018. Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics. Int. J. Pharm. 536(1):116-126. doi: https:\/\/doi.org\/10.1016\/j.ijpharm.2017.11.049. Epub 2017 Nov 24. PMID: 29180257.","DOI":"10.1016\/j.ijpharm.2017.11.049"},{"issue":"10","key":"10.1016\/j.jconrel.2023.12.012_bb0750","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tips.2020.08.002","article-title":"Inhaled RNA therapy: from promise to reality","volume":"41","author":"Chow","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0755","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14356\/kona.2016014","article-title":"Aerosol delivery of siRNA to the lungs. Part 1: rationale for gene delivery systems","volume":"33","author":"Youngren-Ortiz","year":"2016","journal-title":"KONA Powder Part. J."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0760","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2019.10.026","article-title":"Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide","volume":"314","author":"Qiu","year":"2019","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0765","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ijpharm.2012.05.013","article-title":"Pulmonary delivery of dry powders to rats: tolerability limits of an intra-tracheal administration model","volume":"434","author":"Guillon","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0770","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jconrel.2018.04.003","article-title":"Development of spray-freeze-dried siRNA\/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activity","volume":"279","author":"Okuda","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.12.012_bib1410","doi-asserted-by":"crossref","unstructured":"Wen Wang, Zhi Liu, Jie Su, Wen-Sheng Chen, Xiao-Wu Wang, San-Xing Bai, Jin-Zhou Zhang, Shi-Qiang Yu. 2016. Macrophage micro-RNA-155 promotes lipopolysaccharide-induced acute lung injury in mice and rats. Am J Physiol Lung Cell Mol Physiol. 311(2):L494-506.doi: https:\/\/doi.org\/10.1152\/ajplung.00001.2016. Epub 2016 Jul 1. PMID: 27371731.","DOI":"10.1152\/ajplung.00001.2016"},{"issue":"27","key":"10.1016\/j.jconrel.2023.12.012_bb0780","doi-asserted-by":"crossref","first-page":"30095","DOI":"10.1021\/acsami.0c06608","article-title":"Combined chemisorption and complexation generate siRNA Nanocarriers with biophysics optimized for efficient gene knockdown and air-blood barrier crossing","volume":"12","author":"Taschauer","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"11","key":"10.1016\/j.jconrel.2023.12.012_bb0785","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1517\/17425240903241788","article-title":"Preclinical models for pulmonary drug delivery","volume":"6","author":"Fernandes","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0790","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1097\/01.CCM.0000233879.58720.87","article-title":"Clinical practice and risk factors for immediate complications of endotracheal intubation in the intensive care unit: a prospective, multiple-center study","volume":"34","author":"Jaber","year":"2006","journal-title":"Crit. Care Med."},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb0795","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1021\/acs.biomac.7b00572","article-title":"Anti-inflammatory effect of anti-TNF-\u03b1 SiRNA cationic phosphorus dendrimer Nanocomplexes administered Intranasally in a murine acute lung injury model","volume":"18","author":"Bohr","year":"2017","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0800","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pupt.2010.03.007","article-title":"RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice","volume":"23","author":"Gutbier","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0805","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594470","article-title":"Distribution of droplets and immune responses after aerosol and intra-nasal delivery of influenza virus to the respiratory tract of pigs","volume":"11","author":"Martini","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105857","article-title":"The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease","volume":"161","author":"Mahler","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.jconrel.2023.12.012_bib1411","doi-asserted-by":"crossref","unstructured":"Alan B. Watts, Jason T. McConville, Robert O. Williams 3rd. 2008. Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm. 34(9):913-22. doi: https:\/\/doi.org\/10.1080\/03639040802144211. PMID: 18663654.","DOI":"10.1080\/03639040802144211"},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0815","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/17425247.2015.995087","article-title":"Nebulizers for drug delivery to the lungs","volume":"12","author":"Martin","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb0820","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1517\/17425247.2015.1014339","article-title":"Factors to consider when selecting a nebulizer for a new inhaled drug product development program","volume":"12","author":"Elphick","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0825","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/0970-2113.92361","article-title":"Pulmonary drug delivery strategies: a concise, systematic review","volume":"29","author":"Patil","year":"2012","journal-title":"Lung India"},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137504","article-title":"Nebulisation of IVT mRNA complexes for intrapulmonary administration","volume":"10","author":"Johler","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0835","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajps.2018.09.009","article-title":"Apoptosis of A549 cells by small interfering RNA targeting survivin delivery using poly-\u03b2-amino ester\/guanidinylated O-carboxymethyl chitosan nanoparticles","volume":"15","author":"Tang","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0840","article-title":"Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery","volume":"13","author":"van Rijn","year":"2023","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb1040","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1089\/jamp.2013.1045","article-title":"Early-stage development of novel cyclodextrin-siRNA nanocomplexes allows for successful postnebulization transfection of bronchial epithelial cells","volume":"27","author":"Hibbitts","year":"2014","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb0910","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12195-020-00619-y","article-title":"Naturally derived membrane lipids impact nanoparticle-based messenger RNA delivery","volume":"13","author":"Kim","year":"2020","journal-title":"Cell. Mol. Bioeng."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2011.08.008","article-title":"Factors influencing polycation\/siRNA colloidal stability toward aerosol lung delivery","volume":"80","author":"Steele","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1050","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jconrel.2022.10.052","article-title":"Nebulization of extracellular vesicles: a promising small RNA delivery approach for lung diseases","volume":"352","author":"Han","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.12.012_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2022.105178","article-title":"Synthesis and bioactivity of readily hydrolysable novel cationic lipids for potential lung delivery application of mRNAs","volume":"243","author":"Pei","year":"2022","journal-title":"Chem. Phys. Lipids"},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0915","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/nat.2022.0049","article-title":"Aerosolized pulmonary delivery of mRNA constructs attenuates severity of Escherichia coli pneumonia in the rat","volume":"33","author":"McCarthy","year":"2023","journal-title":"Nucleic Acid Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb1060","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ymthe.2020.02.001","article-title":"Precise targeting of miRNA sites restores CFTR activity in CF bronchial epithelial cells","volume":"28","author":"De Santi","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1065","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41563-022-01404-0","article-title":"Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung","volume":"22","author":"Rotolo","year":"2022","journal-title":"Nat. Mater."},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb1070","article-title":"Inhaled Nanoformulated mRNA Polyplexes for protein production in lung epithelium","volume":"31","author":"Patel","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1075","article-title":"Combinatorial development of nebulized mRNA delivery formulations for the lungs","author":"Jiang","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"25","key":"10.1016\/j.jconrel.2023.12.012_bb1080","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn7162","article-title":"Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge","volume":"8","author":"Bai","year":"2022","journal-title":"Sci Adv."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb1085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/1061186X.2016.1278219","article-title":"Nebulized anionic guanidinylated O-carboxymethyl chitosan\/N-2-hydroxypropyltimehyl ammonium chloride chitosan nanoparticles for siRNA pulmonary delivery: preparation, characterization and in vitro evaluation","volume":"25","author":"Ni","year":"2017","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1090","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-00662-2","article-title":"Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis","volume":"7","author":"Manunta","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.ultsonch.2022.106088","article-title":"Nebulization of siRNA for inhalation therapy based on a microfluidic surface acoustic wave platform","volume":"88","author":"Cortez-Jugo","year":"2022","journal-title":"Ultrason. Sonochem."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","author":"Rowe","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"7","key":"10.1016\/j.jconrel.2023.12.012_bb0850","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202102145","article-title":"Toward gene transfer nanoparticles as therapeutics","volume":"11","author":"Kavanagh","year":"2022","journal-title":"Adv. Healthcare Materials"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0855","article-title":"Development of novel therapeutics for all individuals with CF (the future goes on)","author":"Amaral","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0860","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4155\/tde-2017-0102","article-title":"Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments","volume":"9","author":"Pritchard","year":"2018","journal-title":"Ther. Deliv."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb0865","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2007.02.035","article-title":"The influence of fluid physicochemical properties on vibrating-mesh nebulization","volume":"339","author":"Ghazanfari","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0870","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/jphp.12541","article-title":"The function and performance of aqueous aerosol devices for inhalation therapy","volume":"68","author":"Carvalho","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0875","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/17425247.2010.485608","article-title":"Ultrasonic nebulization platforms for pulmonary drug delivery","volume":"7","author":"Yeo","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0880","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11095-016-2061-7","article-title":"SPECT-CT comparison of lung deposition using a system combining a vibrating-mesh nebulizer with a Valved holding chamber and a conventional jet nebulizer: a randomized cross-over study","volume":"34","author":"Dugernier","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0885","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2147\/COPD.S252435","article-title":"Nebulized therapies in copd: past, present, and the future","volume":"15","author":"Barjaktarevic","year":"2020","journal-title":"Int. J. COPD"},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb0890","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/jamp.2008.0717","article-title":"Optimized aerosol delivery to a mechanically ventilated rodent","volume":"22","author":"MacLoughlin","year":"2009","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0895","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/jamp.2020.1615","article-title":"Reducing aerosol-related risk of transmission in the era of COVID-19: an interim guidance endorsed by the International Society of Aerosols in medicine","volume":"33","author":"Fink","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0900","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020199","article-title":"Nebuliser type influences both patient-derived bioaerosol emissions and ventilation parameters during mechanical ventilation","volume":"13","author":"Joyce","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb0905","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11020075","article-title":"Investigation of the quantity of exhaled aerosols released into the environment during nebulisation","volume":"11","author":"McGrath","year":"2019","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0920","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/(SICI)1099-0496(199812)26:6<412::AID-PPUL6>3.0.CO;2-O","article-title":"Drug administration by jet nebulization","volume":"26","author":"Coates","year":"1998","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0925","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0169-409X(03)00077-2","article-title":"Inhalation therapy: technological milestones in asthma treatment","author":"Dalby","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb0930","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080406","article-title":"Aerosolization performance of jet nebulizers and biopharmaceutical aspects","volume":"11","author":"Adorni","year":"2019","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb0935","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.4187\/respcare.02061","article-title":"Breath-actuated nebulizer for patients with exacerbation of COPD: efficiency and cost","volume":"57","author":"Lin","year":"2012","journal-title":"Respir. Care"},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb0940","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1378\/chest.126.5.1619","article-title":"Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency","volume":"126","author":"Leung","year":"2004","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb0945","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.4187\/respcare.01995","article-title":"Breath-actuated nebulizer versus small-volume nebulizer: efficacy, safety, and satisfaction","volume":"57","author":"Ari","year":"2012","journal-title":"Respir. Care"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0950","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/17434440.5.1.9","article-title":"Pulmonary drug delivery system for inhalation therapy in mechanically ventilated patients","volume":"5","author":"Dhand","year":"2008","journal-title":"Expert Rev. Med. Devices"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108601","article-title":"Recent advances in aerosolised drug delivery","volume":"112","author":"Chandel","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb0960","first-page":"609","article-title":"Nebulizers: principles and performance","volume":"45","author":"Hess","year":"2000","journal-title":"Respir. Care"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.11.004","article-title":"Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements","volume":"54","author":"Rangaraj","year":"2019","journal-title":"Pulmonary Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0970","doi-asserted-by":"crossref","DOI":"10.1248\/cpb.c15-00615","article-title":"Inhalation Properties and Stability of Nebulized Naked siRNA Solution for Pulmonary Therapy","volume":"64","author":"Tahara","year":"2016","journal-title":"Chemical and Pharmaceutical Bulletin"},{"key":"10.1016\/j.jconrel.2023.12.012_bb0975","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1016\/j.ymthe.2006.08.782","article-title":"Analysis of the stability and functionality of siRNA after nebulization of siRNA Polyplexes","volume":"13","author":"Huth","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2023.12.012_bb0985","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-fluid-010313-141418","article-title":"Surface acoustic wave microfluidics","volume":"46","author":"Yeo","year":"2014","journal-title":"Annu. Rev. Fluid Mech."},{"issue":"15","key":"10.1016\/j.jconrel.2023.12.012_bb0990","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1039\/b903575c","article-title":"Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization","volume":"9","author":"Qi","year":"2009","journal-title":"Lab Chip"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb0995","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4187\/respcare.02490","article-title":"Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model","volume":"60","author":"Sidler-Moix","year":"2015","journal-title":"Respir. Care"},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb1000","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/thx.52.2008.S31","article-title":"The science of nebulised drug delivery","volume":"52","author":"O\u2019Callaghan","year":"1997","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1016282502954","article-title":"Some factors associated with the ultrasonic nebulization of proteins","volume":"12","author":"Niven","year":"1995","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1010","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1030-1","article-title":"Effective nebulization of interferon-\u03b3 using a novel vibrating mesh","volume":"20","author":"Sweeney","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1015","series-title":"US20230182162A1","author":"MacLoughlin","year":"2023"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb1020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2009.10.012","article-title":"Surface active drugs significantly alter the drug output rate from medical nebulizers","volume":"384","author":"Arzhavitina","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb1025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejpb.2014.03.001","article-title":"That\u2019s cool! - nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer","volume":"87","author":"Hertel","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb1030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0928-0987(03)00148-9","article-title":"Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers","volume":"19","author":"Steckel","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/S0378-5173(97)00105-1","article-title":"Ultrasonic Nebulisers for Pulmonary Drug Delivery","volume":"153","author":"Taylor","year":"1997","journal-title":"International Journal of Pharmaceutics"},{"issue":"36","key":"10.1016\/j.jconrel.2023.12.012_bb1095","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/sj.onc.1206733","article-title":"Use of adeno-associated viral vector for delivery of small interfering RNA","volume":"22","author":"Tomar","year":"2003","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb1100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/abbs\/gms115","article-title":"Adenovirus-mediated delivery of siRNA targeting TM4SF4 attenuated liver cancer cell growth in vitro and in vivo","volume":"45","author":"Wang","year":"2013","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virusres.2011.08.004","article-title":"Intracerebral delivery of small interfering RNAs (siRNAs) using adenoviral vector protects mice against lethal peripheral rabies challenge","volume":"163","author":"Gupta","year":"2012","journal-title":"Virus Res."},{"issue":"36","key":"10.1016\/j.jconrel.2023.12.012_bb1110","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7624","key":"10.1016\/j.jconrel.2023.12.012_bb1115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature19764","article-title":"In vitro and ex vivo strategies for intracellular delivery","volume":"538","author":"Stewart","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.12.012_bb1120","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms2905","article-title":"An influenza virus-inspired polymer system for the timed release of siRNA","volume":"4","author":"Truong","year":"2013","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.jconrel.2023.12.012_bb1125","doi-asserted-by":"crossref","DOI":"10.2174\/1381612821666150531164540","article-title":"Lipid-Based Nanocarriers for RNA Delivery","volume":"21","author":"Xue","year":"2015","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1130","doi-asserted-by":"crossref","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"issue":"15","key":"10.1016\/j.jconrel.2023.12.012_bb1135","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-05-0530","article-title":"Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery","volume":"65","author":"Landen","year":"2005","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.jconrel.2023.12.012_bb1140","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-06-0021","article-title":"Focal Adhesion KinaseTargeting Using in Vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian CarcinomaTherapy","volume":"12","author":"Halder","year":"2006","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1145","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomed. Dovepress"},{"key":"10.1016\/j.jconrel.2023.12.012_bb1150","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.omtm.2020.07.015","article-title":"Barriers and strategies of cationic liposomes for cancer gene therapy","volume":"18","author":"Liu","year":"2020","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1155","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.colsurfa.2018.06.073","article-title":"Evaluation of siRNA and cationic liposomes complexes as a model for in vitro siRNA delivery to cancer cells","volume":"555","author":"E\u015f","year":"2018","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb1160","doi-asserted-by":"crossref","DOI":"10.1023\/A:1007504613351","article-title":"Oxygen Radical-Mediated Pulmonary Lack of Immunogenicity, Simplicity and Ease of Production Make","volume":"17","author":"Dokka","year":"2000","journal-title":"Pharm Res."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1165","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.addr.2013.12.008","article-title":"Liposomal siRNA nanocarriers for cancer therapy","volume":"66","author":"Ozpolat","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2015.06.028","article-title":"Multicomponent mannose-containing liposomes efficiently deliver RNA in murine immature dendritic cells and provide productive anti-tumour response in murine melanoma model","volume":"213","author":"Markov","year":"2015","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb1175","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/1061186X.2018.1502775","article-title":"Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex","volume":"27","author":"Hattori","year":"2018","journal-title":"J. Drug Target."},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb1180","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/adhm.201500910","article-title":"A Micro\/Nano composite for combination treatment of melanoma lung metastasis","volume":"5","author":"Mi","year":"2016","journal-title":"Adv. Healthc. Mater."},{"issue":"6\u20137","key":"10.1016\/j.jconrel.2023.12.012_bb1185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/01902148.2017.1354946","article-title":"Treatment of pulmonary fibrosis with siRNA against a collagen-specific chaperone HSP47 in vitamin A-coupled liposomes","volume":"43","author":"Otsuka","year":"2017","journal-title":"Exp. Lung Res."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb1190","doi-asserted-by":"crossref","DOI":"10.1038\/sj.gt.3300596","article-title":"Time-Dependent Maturation of Cationic Liposome-DNA Complex for Serum Resistance","volume":"5","author":"Yang","year":"1998","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1195","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jconrel.2023.12.012_bb1200","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17425247.2019.1669558","article-title":"Lipid-based nanoparticle formulations for small molecules and RNA drugs","volume":"16","author":"Ickenstein","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","article-title":"From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases","volume":"131","author":"Pilkington","year":"2021","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb1210","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng. Transl. Med."},{"issue":"15","key":"10.1016\/j.jconrel.2023.12.012_bb1215","first-page":"E3351","article-title":"Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles","volume":"115","author":"Arteta","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb1220","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.27361","article-title":"Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo","volume":"131","author":"Lee","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"19","key":"10.1016\/j.jconrel.2023.12.012_bb1225","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/0008-5472.CAN-12-1871","article-title":"Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth","volume":"72","author":"Kang","year":"2012","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb1230","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.nano.2016.12.014","article-title":"Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA","volume":"13","author":"Kulkarni","year":"2017","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb1235","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103505","article-title":"Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids","volume":"28","author":"Mendon\u00e7a","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.12.012_bb1240","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.589959","article-title":"Advances in lipid nanoparticles for mRNA-based cancer immunotherapy","volume":"8","author":"Guevara","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1245","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: Non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1250","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jconrel.2023.12.012_bb1255","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/acs.molpharmaceut.8b01290","article-title":"Lipid nanoparticles for delivery of therapeutic RNA oligonucleotides","volume":"16","author":"Moss","year":"2019","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb1260","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00018-011-0856-6","article-title":"Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications","volume":"69","author":"Galvin","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb1265","article-title":"Immunogenicity of polyethylene glycol based nanomedicines: mechanisms, clinical implications and systematic approach","volume":"3","author":"d\u2019Avanzo","year":"2020","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb1270","article-title":"The importance of Poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Thi","year":"2020","journal-title":"Polymers"},{"issue":"13","key":"10.1016\/j.jconrel.2023.12.012_bb1275","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.addr.2011.09.003","article-title":"Using drug-excipient interactions for siRNA delivery","volume":"63","author":"Bruno","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1039\/9781849735292-00063","article-title":"Nanostructures overcoming the intestinal barrier: drug delivery strategies","author":"Ryan","year":"2012","journal-title":"Nanostruct. Biomater. Overcoming Biol. Barriers"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1285","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/10717544.2018.1440668","article-title":"Water-Soluble Substituted Chitosan Derivatives as Technology Platform for Inhalation Delivery of siRNA","volume":"25","author":"Capel","year":"2018","journal-title":"Drug Deliv"},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb1290","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ymthe.2006.04.010","article-title":"RNA interference in vitro and in vivo using a novel chitosan\/siRNA nanoparticle system","volume":"14","author":"Howard","year":"2006","journal-title":"Mol Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1295","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaci.2007.08.029","article-title":"Effect of chemically modified IL-13 short interfering RNA on development of airway hyperresponsiveness in mice","volume":"121","author":"Lively","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.jconrel.2023.12.012_bb1300","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1007\/s11095-013-1084-6","article-title":"BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs","volume":"30","author":"Chitkara","year":"2013","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb1305","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.actbio.2013.12.050","article-title":"Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells","volume":"10","author":"Heo","year":"2014","journal-title":"Acta Biomater."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb1310","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/wnan.1228","article-title":"Polyethylenimines for siRNA and miRNA delivery in vivo","volume":"5","author":"H\u00f6bel","year":"2013","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"8","key":"10.1016\/j.jconrel.2023.12.012_bb1315","doi-asserted-by":"crossref","DOI":"10.1038\/sj.gt.3300471","article-title":"Polyethylenimine (PEI) Is a Simple, Inexpensive and Effective Reagent for Condensing and Linking Plasmid DNA to Adenovirus for Gene Delivery","volume":"4","author":"Baker","year":"1997","journal-title":"Gene Ther."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.12.012_bb1320","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijpharm.2017.02.048","article-title":"Cytotoxicity of polycations: relationship of molecular weight and the hydrolytic theory of the mechanism of toxicity","volume":"521","author":"Monnery","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb1325","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1021\/bc800428y","article-title":"A biodegradable low molecular weight polyethylenimine derivative as low toxicity and efficient gene vector","volume":"20","author":"Wen","year":"2009","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb1330","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ejpb.2012.07.021","article-title":"PLGA microspheres encapsulating siRNA anti-TNFalpha: efficient RNAi-mediated treatment of arthritic joints","volume":"82","author":"Pr\u00e9sumey","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1335","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/IJN.S40579","article-title":"Concepts and practices used to develop functional PLGA-based nanoparticulate systems","volume":"8","author":"Sah","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.12.012_bb1340","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.39","article-title":"Acid-sensitive Sheddable PEGylated PLGA nanoparticles increase the delivery of TNF-\u03b1 siRNA in chronic inflammation sites","volume":"5","author":"Aldayel","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1345","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2011.08.011","article-title":"Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA","volume":"157","author":"Jensen","year":"2012","journal-title":"J. Control. Release"},{"issue":"4\u20135","key":"10.1016\/j.jconrel.2023.12.012_bb1350","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejps.2012.12.017","article-title":"Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating","volume":"48","author":"Jagani","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.12.012_bb1355","article-title":"Nanoplatforms for mRNA therapeutics","volume":"4","author":"Meng","year":"2021","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2023.12.012_bb1360","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1365","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2023.12.012_bb1370","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.addr.2006.03.001","article-title":"Natural polymers for gene delivery and tissue engineering","volume":"58","author":"Dang","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2023.12.012_bb1375","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.progpolymsci.2006.06.001","article-title":"Chitin and chitosan: properties and applications","volume":"31","author":"Rinaudo","year":"2006","journal-title":"Prog. Polym. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.012_bb1380","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2006.07.021","article-title":"Development and characterisation of chitosan nanoparticles for siRNA delivery","volume":"115","author":"Katas","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.12.012_bb1385","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijbiomac.2019.02.036","article-title":"Optimization of chitosan nanoparticles as an anti-HIV siRNA delivery vehicle","volume":"129","author":"Iranpur Mobarakeh","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1390","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s11095-010-0255-y","article-title":"Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan\/siRNA nanoparticles","volume":"27","author":"Nielsen","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1395","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejpb.2017.07.014","article-title":"Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: a quality by design-based approach","volume":"120","author":"Thanki","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.012_bb1400","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","article-title":"Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review","volume":"85","author":"Hadinoto","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.12.012_bb1405","doi-asserted-by":"crossref","DOI":"10.1002\/ejlt.201300404","article-title":"Nebulization of Liposome-Polyethylenimine Complexes (Lipopolyplexes) for DNA or siRNA Delivery: Physicochemical Properties and Biological Activity","volume":"116","author":"Ewe","year":"2014","journal-title":"Eur. J. Lipid Sci. Technol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923007964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923007964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T21:31:38Z","timestamp":1738099898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923007964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":285,"alternative-id":["S0168365923007964"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.12.012","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}